---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-038678"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2021-07-28T23:59:59+00:00"
generated_at: "2026-06-30T01:40:24.954215+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Viking Therapeutics enters $125M ATM equity offering; terminates prior $75M facility

## Summary
- Entered $125M ATM agreement with Stifel, Truist, and H.C. Wainwright for common stock sales at market prices.
- Agents receive 3.0% commission on gross proceeds from sales under the new ATM facility.
- Proceeds to fund continued development of VK2809 and VK0214 programs and general corporate purposes.
- Terminated prior $75M ATM agreement (Aug 2019) with Stifel and Oppenheimer; no shares ever sold under that facility.
- Registration statement for the $125M offering filed but not yet effective; shares may not be sold until effective.

## SEC filing metadata
- accession: 0001564590-21-038678
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2021-07-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000156459021038678/0001564590-21-038678-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000156459021038678/vktx-8k_20210728.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-038678
- JSON: https://secwatch.observer/filing/0001564590-21-038678.json
- Plain text: https://secwatch.observer/filing/0001564590-21-038678.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.